Whereby the reviews could summarize the work on key targets (e.g., PD-1, PDL-1, CD8), different imaging modalities (e.g., SPECT, PET, MRI), entities (antibody, peptide, etc.), and different tumor models, we thought it would be necessary to discuss new ways to approach the problem and to evaluate if and how already published work can progress into a product that is reliable and efficient for therapy evaluation. Here, CD8A is linked to neoplasm.